519 related articles for article (PubMed ID: 28603071)
21. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
Cordas Dos Santos DM; Saliba RM; Patel R; Bashir Q; Saini N; Hosing C; Kebriaei P; Khouri IF; Nieto Y; Popat U; Ahmed H; Lee HC; Manasanch EE; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1077-1083. PubMed ID: 31786242
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
23. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Belotti A; Ribolla R; Cancelli V; Crippa C; Bianchetti N; Ferrari S; Bottelli C; Cattaneo C; Tucci A; De La Fuente Barrigon C; Rossi G
Am J Hematol; 2020 Jul; 95(7):759-765. PubMed ID: 32242970
[TBL] [Abstract][Full Text] [Related]
24. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
25. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
[TBL] [Abstract][Full Text] [Related]
26. Edentulism and transplant-associated complications in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Toro JJ; Gushiken FC; Schneider D; Lee S; Haile DJ; Freytes CO
Support Care Cancer; 2016 Aug; 24(8):3411-5. PubMed ID: 26984247
[TBL] [Abstract][Full Text] [Related]
27. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
28. Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation.
Mohyuddin GR; Abbasi S; Okoniewski M; McClune B; Abdallah AO; Ganguly S; McGuirk J; Shune L
Eur J Haematol; 2020 Nov; 105(5):571-577. PubMed ID: 32662224
[TBL] [Abstract][Full Text] [Related]
29. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.
Yadav N; Mirgh SP; Aggarwal M; Agrawal N; Mehta P; Khushoo V; Kapoor J; Bhatia N; Agrawal P; Ahmed R; Bhurani D
Indian J Cancer; 2023; 60(3):316-324. PubMed ID: 37787191
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
[TBL] [Abstract][Full Text] [Related]
31. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
Garderet L; Iacobelli S; Koster L; Goldschmidt H; Johansson JE; Bourhis JH; Krejci M; Leleu X; Potter M; Blaise D; Koenecke C; Peschel C; Radocha J; Metzner B; Lenain P; Schäfer-Eckart K; Pohlreich D; Grasso M; Caillot D; Einsele H; Ladetto M; Schönland S; Kröger N
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1372-1378. PubMed ID: 29408334
[TBL] [Abstract][Full Text] [Related]
32. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
[TBL] [Abstract][Full Text] [Related]
33. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
34. Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape.
Borgsten F; Gatopoulou X; Pisini M; Tambour M; Schain F; Jones CV; Kwok KHM; Batyrbekova N; Björkholm M
Eur J Haematol; 2021 Jul; 107(1):92-103. PubMed ID: 33728732
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit.
Bayraktar UD; Shpall EJ; Liu P; Ciurea SO; Rondon G; de Lima M; Cardenas-Turanzas M; Price KJ; Champlin RE; Nates JL
J Clin Oncol; 2013 Nov; 31(33):4207-14. PubMed ID: 24127454
[TBL] [Abstract][Full Text] [Related]
36. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
Jaglowski SM; Ruppert AS; Hofmeister CC; Elder P; Blum W; Klisovic R; Vasu S; Penza S; Efebera YA; Benson DM; Devine SM; Andritsos LA
Bone Marrow Transplant; 2014 Oct; 49(10):1323-9. PubMed ID: 25068419
[TBL] [Abstract][Full Text] [Related]
37. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
38. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma.
Labonté L; Iqbal T; Zaidi MA; McDiarmid SA; Huebsch LB; Tay J; Atkins H; Allan DS
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1039-1044. PubMed ID: 18721767
[TBL] [Abstract][Full Text] [Related]
39. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
[TBL] [Abstract][Full Text] [Related]
40. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
